跳至主要内容
临床试验/TCTR20240722001
TCTR20240722001招募中2 期

Efficacy of a reduced-sodium salt substitute on blood pressure in hypertensive patients

/A0 个研究点目标入组 64 人开始时间: 2024年7月22日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
64

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
40 Years 至 80 Years(—)
性别
All

入选标准

  • Patients older than 40 years with a diagnosis of Essential or Primary Hypertension.

排除标准

  • Have salt-losing nephropathy.
  • Received drugs that affect sodium in the body, such as thiazide drugs, furosemide, etc.
  • Patients with swelling due to high ECF causing low sodium. such as patients with heart failure, liver failure
  • Patients with chronic kidney disease stage 3b (CKD stage3b) and above or GFR<45mL/min/1.73 squaremeter
  • Patients with syndrome of inappropriate ADH secretion (SIADH).
  • Participants who ate out more than once per week.
  • Participants with food allergies to soybeans. Wheat and oysters
  • Those who do not agree to act according to the doctor's advice in accordance with the research protocol. or have a physical mental disorder that affects the follow-up of the research study
  • Patients diagnosed with Hypertensive urgency or Hypertensive emergency.
  • Participants who cannot read Thai and cannot write letters.

研究者

发起方
/A

相似试验